AR122018A1 - Proteínas que se unen a nkg2d, cd16 y clec12a - Google Patents
Proteínas que se unen a nkg2d, cd16 y clec12aInfo
- Publication number
- AR122018A1 AR122018A1 ARP210101229A ARP210101229A AR122018A1 AR 122018 A1 AR122018 A1 AR 122018A1 AR P210101229 A ARP210101229 A AR P210101229A AR P210101229 A ARP210101229 A AR P210101229A AR 122018 A1 AR122018 A1 AR 122018A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding proteins
- nkg2d
- clec12a
- clec12a binding
- multispecific binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Aquí se describen proteínas de unión multiespecíficas que se unen al receptor NKG2D, CD16 y CLEC12A, composiciones farmacéuticas que comprenden las proteínas de unión multiespecíficas, y métodos terapéuticos útiles para el tratamiento del cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063020798P | 2020-05-06 | 2020-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122018A1 true AR122018A1 (es) | 2022-08-03 |
Family
ID=78468474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101229A AR122018A1 (es) | 2020-05-06 | 2021-05-05 | Proteínas que se unen a nkg2d, cd16 y clec12a |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220119534A1 (es) |
EP (1) | EP4146271A1 (es) |
KR (1) | KR20230008181A (es) |
CN (1) | CN115836088A (es) |
AR (1) | AR122018A1 (es) |
AU (1) | AU2021268340A1 (es) |
BR (1) | BR112022021884A2 (es) |
CA (1) | CA3177024A1 (es) |
CL (1) | CL2022003077A1 (es) |
CO (1) | CO2022015929A2 (es) |
IL (1) | IL297922A (es) |
MX (1) | MX2022013944A (es) |
TW (1) | TW202208428A (es) |
WO (1) | WO2021226193A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3126384B1 (en) * | 2014-04-01 | 2020-12-02 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
BR112020016939A2 (pt) * | 2018-02-20 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso |
WO2023107956A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023201238A1 (en) * | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
JP2019507581A (ja) * | 2015-11-09 | 2019-03-22 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータのエピトープおよびそれに対する立体配座選択的抗体 |
EP3851457A1 (en) * | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
CN110267678A (zh) * | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
SG11201913969SA (en) * | 2017-08-16 | 2020-01-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1 |
WO2019055677A1 (en) * | 2017-09-14 | 2019-03-21 | Dragonfly Therapeutics, Inc. | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
JP2021514206A (ja) * | 2018-02-20 | 2021-06-10 | ドラゴンフライ セラピューティクス, インコーポレイテッド | Cd33を標的とする抗体可変ドメイン及びその使用 |
WO2020073131A1 (en) * | 2018-10-10 | 2020-04-16 | Zymeworks Inc. | Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof |
-
2021
- 2021-05-05 WO PCT/US2021/030821 patent/WO2021226193A1/en active Application Filing
- 2021-05-05 CA CA3177024A patent/CA3177024A1/en active Pending
- 2021-05-05 MX MX2022013944A patent/MX2022013944A/es unknown
- 2021-05-05 KR KR1020227042774A patent/KR20230008181A/ko active Search and Examination
- 2021-05-05 EP EP21800226.9A patent/EP4146271A1/en active Pending
- 2021-05-05 BR BR112022021884A patent/BR112022021884A2/pt unknown
- 2021-05-05 AR ARP210101229A patent/AR122018A1/es unknown
- 2021-05-05 AU AU2021268340A patent/AU2021268340A1/en active Pending
- 2021-05-05 TW TW110116242A patent/TW202208428A/zh unknown
- 2021-05-05 IL IL297922A patent/IL297922A/en unknown
- 2021-05-05 US US17/308,691 patent/US20220119534A1/en active Pending
- 2021-05-05 CN CN202180047702.3A patent/CN115836088A/zh active Pending
-
2022
- 2022-11-04 CO CONC2022/0015929A patent/CO2022015929A2/es unknown
- 2022-11-04 CL CL2022003077A patent/CL2022003077A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022015929A2 (es) | 2023-02-16 |
BR112022021884A2 (pt) | 2022-12-20 |
CN115836088A (zh) | 2023-03-21 |
TW202208428A (zh) | 2022-03-01 |
WO2021226193A1 (en) | 2021-11-11 |
KR20230008181A (ko) | 2023-01-13 |
IL297922A (en) | 2023-01-01 |
MX2022013944A (es) | 2022-11-30 |
CL2022003077A1 (es) | 2023-07-21 |
AU2021268340A1 (en) | 2022-12-08 |
US20220119534A1 (en) | 2022-04-21 |
JP2023508942A (ja) | 2023-03-06 |
EP4146271A1 (en) | 2023-03-15 |
CA3177024A1 (en) | 2021-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122018A1 (es) | Proteínas que se unen a nkg2d, cd16 y clec12a | |
CO2022004757A2 (es) | Proteínas que se unen a nkg2d, cd16 y flt3 | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
CL2023002108A1 (es) | Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CO2020001981A2 (es) | Proteínas que se unen a nkg2d, cd16 y flt3 | |
CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
EP3882270A3 (en) | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 | |
CL2021002586A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
MX2019009848A (es) | Proteínas que se unen a her2, nkg2d y cd16. | |
CL2021000316A1 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
CO2022017348A2 (es) | Anticuerpos anti-tigit | |
CO2024003967A2 (es) | Proteínas que se unen a nkg2d, cd16 y baff-r | |
MX2019009541A (es) | Proteinas que se unen a psma, nkg2d y cd16. | |
MX2019009943A (es) | Proteínas que se unen a gd2, nkg2d y cd16. | |
CO2022003703A2 (es) | Conjugados terapéuticos | |
BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
BR112023002116A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e egfr | |
MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
AR127896A1 (es) | Proteínas que se unen a nkg2d, cd16 y 5t4 | |
AR122120A1 (es) | Moléculas de fijación para el tratamiento de cáncer | |
CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer |